Processa Pharmaceuticals (PCSA) Liabilities from Discontinued Operations (2014 - 2016)
Processa Pharmaceuticals' (PCSA) quarterly Liabilities from Discontinued Operations came in at 307219.0 in Q1 2016, up 2.29% on a QoQ basis from 300338.0 in Q4 2015.
Processa Pharmaceuticals (PCSA) Liabilities from Discontinued Operations (2014 - 2016) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 3 years of Liabilities from Discontinued Operations data on file, last reported at 307219.0 in Q1 2016.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 307219.0 in Q1 2016, while the trailing twelve-month figure through Mar 2016 was 307219.0 (changed N/A YoY) and the FY2015 annual result came in at 300338.0, down 33.73% from the prior year.
- Liabilities from Discontinued Operations climbed to 307219.0 in Q1 2016, from 300338.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 453193.0 in Q4 2014 to a low of 43549.0 in Q3 2015.
- A 3-year average of 276074.75 and a median of 303778.5 in 2015 frame the typical range for Liabilities from Discontinued Operations.
- The widest YoY moves for Liabilities from Discontinued Operations: up 33.73% in 2015, down 33.73% in 2015.
- Tracing PCSA's Liabilities from Discontinued Operations over 3 years: stood at 453193.0 in 2014, then sank by 33.73% to 300338.0 in 2015, then advanced by 2.29% to 307219.0 in 2016.
- The last three Liabilities from Discontinued Operations figures came in at 307219.0 (Q1 2016), 300338.0 (Q4 2015), and 43549.0 (Q3 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 307,219.00 |
| Mar 31, 2016 | 307,219.00 |
| Dec 31, 2015 | 300,338.00 |
| Dec 31, 2015 | 300,338.00 |
| Sep 30, 2015 | 43,549.00 |
| Sep 30, 2015 | 43,549.00 |
| Dec 31, 2014 | 453,193.00 |
| Dec 31, 2014 | 453,193.00 |